At a glance
- Originator Merck & Co
- Class Anti-ischaemics; Antihyperlipidaemics; Benzoic acids; Prostaglandins
- Mechanism of Action Prostaglandin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Ischaemic heart disorders
Most Recent Events
- 02 Aug 1995 Discontinued-II for Hypertension in United Kingdom (Unknown route)
- 02 Aug 1995 Discontinued-II for Hypertension in USA (Unknown route)
- 02 Aug 1995 Discontinued-II for Ischaemic heart disorders in United Kingdom (Unknown route)